Higher pre-diagnostic serum syndecan-4 levels are associated with increased breast cancer risk: a case-cohort study

Syndecans are transmembrane proteins involved in inflammation and signaling pathways. Their potential role as pre-diagnostic biomarkers for breast cancer risk remains unexplored. This study aimed to investigate whether pre-diagnostic serum syndecan levels are associated with breast cancer risk in a population-based cohort. We conducted a case-cohort study nested within the Tromsø Study (Norway), including women who participated in the fifth survey (2001). Women with incident breast cancer (cases, n = 158) through 2022 were identified, with a random sub-cohort of 708 women. Serum levels of syndecan-1 (SDC1) and syndecan-4 (SDC4) were measured using ELISA on frozen serum samples obtained in 2001. All participants were stratified into quartiles (Q1–Q4) based on pre-diagnostic levels. Cox proportional hazards regression models assessed associations between serum syndecan levels and breast cancer risk. The median age at diagnosis was 69 years for cases, and 83.3% of tumors were hormone receptor-positive (HR +). Women with higher serum SDC4 (Q2–Q4) levels had approximately a twofold increased risk of breast cancer compared to women in Q1. We observed a nearly threefold increased risk for the HR + subtype. In postmenopausal women, HRs for HR + breast cancer in Q2, Q3, and Q4 were 3.81 (95% CI: 1.57–9.23), 3.43 (95% CI: 1.41–8.40), and 3.54 (95% CI: 1.45–8.65), respectively, all relative to Q1 of SDC4. No associations were observed between SDC1 levels and breast cancer risk. Our results suggest that SDC4 may play a role in the initiation and early progression of breast cancer.

• Publication year

  2025

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2025-07-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10549-025-07786-4PMID 40694191PMCID 12397127
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Modifiable risk factors in women at high risk of breast cancer: a systematic review

  2023cited by this paper
• The association of a combined healthy lifestyle with the risk of postmenopausal breast cancer subtypes in the Netherlands Cohort Study

  2023cited by this paper
• Linking Physical Activity to Breast Cancer via Inflammation, Part 2: The Effect of Inflammation on Breast Cancer Risk

  2023cited by this paper
• Role of Syndecan-4 in breast cancer pathophysiology.

  2022cited by this paper
• Syndecans in cancer: A review of function, expression, prognostic value, and therapeutic significance.

  2021influential reference
• Breast cancer

  2021cited by this paper
• Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study

  2020cited by this paper
• Heparanase-enhanced Shedding of Syndecan-1 and Its Role in Driving Disease Pathogenesis and Progression

  2020cited by this paper
• Inflammatory Biomarkers and Breast Cancer Risk: A Systematic Review of the Evidence and Future Potential for Intervention Research

  2020cited by this paper
• Inflammatory serum markers and risk and severity of prostate cancer: The PROCA‐life study

  2020cited by this paper
• Human Epidermal Growth Factor Receptor

  2019cited by this paper
• Matrix metalloproteinase‐9 mediated shedding of syndecan‐4 in glomerular endothelial cells

  2019cited by this paper
• Faculty Opinions recommendation of Human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of american pathologists clinical practice guideline focused update.

  2019cited by this paper
• Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes

  2018cited by this paper
• Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

  2018cited by this paper
• Gender differences in the association of syndecan-4 with myocardial infarction: The population-based Tromsø Study.

  2018cited by this paper
• Soluble syndecans: biomarkers for diseases and therapeutic options

  2018cited by this paper
• Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size

  2017cited by this paper
• Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival

  2016cited by this paper
• Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication

  2015cited by this paper
• Syndecan-4 Is a Major Syndecan in Primary Human Endothelial Cells In Vitro, Modulated by Inflammatory Stimuli and Involved in Wound Healing

  2015cited by this paper
• The sixth survey of the Tromsø Study (Tromsø 6) in 2007–08: Collaborative research in the interface between clinical medicine and epidemiology: Study objectives, design, data collection procedures, and attendance in a multipurpose population-based health survey

  2013cited by this paper
• Molecular functions of syndecan-1 in disease.

  2012cited by this paper
• Serum syndecan-4 is a novel biomarker for patients with chronic heart failure.

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Syndecan-1 and Syndecan-4 Are Independent Indicators in Breast Carcinoma

  2011cited by this paper
• Cohort profile: The Tromsø Study

  2011cited by this paper
• Proteoglycans in health and disease: the multiple roles of syndecan shedding

  2010influential reference
• The expression of syndecan-1, syndecan-4 and decorin in healthy human breast tissue during the menstrual cycle

  2010cited by this paper
• A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project.

  2007cited by this paper
• [Breast cancer].

  2006influential reference
• Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype

  2006cited by this paper
• Expression Pattern of Metalloproteinases and Tissue Inhibitors of Matrix-Metalloproteinases in Cycling Human Endometrium1

  2003cited by this paper
• Factors associated with age at natural menopause in a multiethnic sample of midlife women.

  2001cited by this paper
• Syndecans, Heparan Sulfate Proteoglycans, Maintain the Proteolytic Balance of Acute Wound Fluids*

  1998cited by this paper
• Regulated Shedding of Syndecan-1 and -4 Ectodomains by Thrombin and Growth Factor Receptor Activation*

  1997cited by this paper
• Syndecans: multifunctional cell-surface co-receptors.

  1997cited by this paper
• Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns.

  1994cited by this paper
• pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up

  1991cited by this paper
• TNM Classification of Malignant Tumours

  1987cited by this paper

• No citing papers are available for this paper.